Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Type I interferon and HIV: Subtle balance between antiviral activity, immunopathogenesis and the microbiome

Carolina Scagnolari, Guido Antonelli

Department of Molecular Medicine, Laboratory of Virology Affiliated to Istituto Pasteur Italia – Fondazione Cenci Bolognetti, Sapienza University, Rome, Italy

ARTICLE INFO

Keywords:
HIV-1
IFN
ISGs
IFN0
IFNα subtypes
Age
Gender
SNP
Microbiome
Gut
PRR
IFNα receptor

ABSTRACT

Type I interferon (IFN) response initially limits HIV-1 spread and may delay disease progression by stimulating several immune system components. Nonetheless, persistent exposure to type I IFN in the chronic phase of HIV-1 infection is associated with desensitization and/or detrimental immune activation, thereby hindering immune recovery and fostering viral persistence. This review provides a basis for understanding the complexity and function of IFN pleiotropic activity in HIV-1 infection. In particular, the dichotomous role of the IFN response in HIV-1 immunopathogenesis will be discussed, highlighting recent advances in the dynamic modulation of IFN production in acute versus chronic infection, expression signatures of IFN subtypes, and viral and host factors affecting the magnitude of IFN response during HIV-1 infection. Lastly, the review gives a forward-looking perspective on the interplay between microbiome compositions and IFN response.

1. Introduction

Despite over 30 years of research, the contribution of type I IFNs to both the control of HIV-1 spread and the initiation of immunologic damage remains controversial [1,2]. As with most viral infections, HIV-1 can efficiently stimulate host antiviral defense responses, but the production of type I IFNs and induction of a large set of ISGs fails to keep the virus entirely in check. Strikingly, and most distressingly for HIV-1-infected patients, prolonged exposure to type I IFN in the chronic phase of infection is associated with desensitization and/or detrimental hyperimmune activation contributing to disease progression [1,2]. This apparently paradoxical action of IFN in HIV-1 infection is also well-established in chronic HCV infection where the majority of patients are unable to clear the virus and develop viral persistence in the face of a rapidly induced ISG response [3–5]. In parallel, when chronically HCV-infected patients with strong ISG expression were treated with IFNα and ribavirin, a virological response was very rare [3–5]. Moreover, when viral infections cannot be cleared, sustained type I IFN signaling seems to assume a predominantly immunosuppressive role, possibly to limit host toxicity and morbidity during persistent infection. Indeed, a direct causal link between type I IFN signaling, immune activation, negative immune regulator expression (e.g. IL-10 and PD-L1), lymphoid tissue disorganization, impaired humoral responses to secondary viral infection, and persistent LCMV has been reported [6–9]. Thus, emerging evidence shows that type I IFN is a common nexus in the pathogenesis of chronic viral diseases.

Interestingly, type I IFNs have been shown to cause immunopathology and/or negative effects even in some acute viral infections (e.g., influenza, severe acute respiratory syndrome-associated coronavirus) and in several bacterial infections [1,10–12].

Abbreviations: IFN, interferon; ISGs, IFN-stimulated genes; HCV, hepatitis C virus; IL-10, interleukin-10; PDL-1, programmed death-ligand 1; LCMV, lymphocytic choriomeningitis virus; IFNAR, IFNα receptor; IRFs, IFN regulatory factors; pDCs, plasmacytoid dendritic cells; JAK-STAT, Janus kinase/signal transducer and activator of transcription; TLR, toll-like receptors; IF01, IFN-α-inducible protein 10; PRRs, pattern recognition receptors; MYD88, myeloid differentiation primary response gene 88; HAART, highly active antiretroviral therapy; GALT, gut-associated lymphoid tissue; MIP-3α, macrophage inflammatory protein 3α; CXCL10, chemokine (C-X-C motif) ligand 10; TRAIL, tumor necrosis factor (TNF)-related apoptosis-inducing ligand; DR5, death receptor 5; Bak, Bcl-2 homologous antagonist/killer; TF, transmitted founder; IFITMs, IFN-induced transmembrane proteins; DCs, dendritic cells; CPSF6, cleavage and polyadenylation specificity factor subunit 6; cGAS, cyclic guanosine monophosphate–adenosine monophosphate synthase; IFI16, IFN-α-inducible protein; TREG1, intracellular enzyme 3’ repair exonuclease; NF-kB, nuclear factor kappa-light-chain-enhancer of B cell; RIG1, retinoic acid-inducible gene 1 protein; SOCS3, suppressor of cytokine signaling 3; PRR, protein kinase R; 2-5AOS, 2′–5′-oligoadenylate synthetase; APOBEC3, apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like; RANTES, bone marrow stromal antigen 2; Mx2, and myxovirus resistance 2; SAMHD1, sterile alpha motif and histidine/aspartic acid domain containing 1; SNP, single nucleotide polymorphism; MSM, men who have sex with men.

* Corresponding author at: Department of Molecular Medicine, Laboratory of Virology Affiliated to Istituto Pasteur Italia – Fondazione Cenci Bolognetti, Sapienza University, Viale di Porta Tiburtina n° 28, 00185, Rome, Italy.

E-mail address: carolina.scagnolari@uniroma1.it (C. Scagnolari).

https://doi.org/10.1016/j.cytogfr.2018.03.003

Received 24 January 2018; Received in revised form 23 February 2018; Accepted 8 March 2018

Available online 16 March 2018

1359-6101/©2018 Elsevier Ltd. All rights reserved.
Given the growing evidence of type I IFN involvement in viral disease progression, it is not surprising that the possibility to target either type I IFN or the mechanisms leading to IFN production in HIV-1 disease has been considered a promising new therapeutic approach

However, the complexity of both the IFN system and HIV-1 immunopathogenesis make the clinical consequences of manipulating type I IFN signaling difficult to predict in vivo. Such therapeutic interventions should therefore be approached with caution in HIV-1 positive subjects. Indeed, several key questions on the controversial role played by type I IFNs in controlling HIV-1 infection remain unanswered despite intense research in this area.

This review attempts to address the above issues summarizing current knowledge of how type I IFN response plays dual roles in HIV-1 replication and disease progression. Emphasis is placed on the importance of type I IFN subtype signature, HIV-1 strategies of IFN evasion, host genetics and the interplay between IFN and the microbiome as the main factors affecting the magnitude of IFN response during HIV-1 infection.

2. IFN system

The IFN system consists of a broad family of cytokines that are key players in the development of both innate and adaptive immune responses. According to their cellular origin and the type of receptors they bind to, IFNs are grouped into three different types (Table 1) [5]. Type I IFN comprises multiple species, all of which signal through the same heterodimeric receptor [IFNA receptor (IFNAR)]. In humans, there are several subtypes of IFNα, one IFNβ, one IFNω, one IFNε, and one IFNκ. In particular, excluding the pseudogenes, there are at least 13 distinct IFNα subtypes, which are genetically and structurally very similar. They all lack introns, their protein sequence is highly conserved (75–99% amino acid sequence identity) and they are clustered on the short arm of chromosome 9 [16]. It is unclear what advantage so many different IFNα subtypes provides, but the in vitro antiviral and antiproliferative activities of the IFNα subtypes vary as do their effects on innate and adaptive immunity [16]. The differences among IFNα subtypes may reveal their variation in affinity for the IFNα receptor or variable signaling through complement receptor type 2 [17]. Furthermore, depending on the cell type and the kind of stimulation, the IFNα subtype pattern expressed is regulated by the differential expression of various IFN regulatory factors (IRFs) [16].

Despite these differences, all IFNα subtypes are mainly produced by pDCs, while fibroblasts are the main source of IFNβ. IFNα and IFNβ are one of the body’s best natural weapons against viruses. After recognition of their specific receptor, all type I IFNs trigger the JAK-STAT pathway leading to the expression of hundreds of ISGs. These ISGs encode proteins that may limit the spread of infection affecting host and/or viral pathways (e.g. retroviral restriction factors). Moreover, both innate and adaptive immune cells respond to type I IFNs by enhancing antigen presentation and chemokine production, increasing antibody production by B cells and amplifying the effector function of T cells [5]. Unlike the multiple type I IFNs, type II IFN includes a single cytokine, IFNγ, mainly secreted by T lymphocytes and NK cells. IFNγ binds to a heterodimeric receptor, IFNGR1/2, and coordinates a wide array of cellular programs through transcriptional regulation of immunologically relevant genes. Type III IFNs are a recently identified class belonging to the IFN system, including four subtypes, IFN-1-4 [18,19]. Among type III IFNs, IFN-4 expression and production are controlled by a dinucleotide polymorphism known as IFNL4 rs368234815 (AG/TT) located in exon 1 of IFNL4, and IFN-4 protein can be produced only by individuals carrying the functional genetic variant IFNL4-AG allele [20]. IFNαs share features with both type I IFNs and the IL-10 family and display type I IFN-like antiviral activity and induction of classical ISGs [20,21]. These functional similarities result from the activation of a common signaling pathway, although IFNαs engage a specific receptor complex composed of IFNLR1 (also known as IL-28RA) and the accessory chain IL-10R2. They have a more tissue-restricted expression than type I IFN, the liver tissues and epithelial cells being highly sensitive to their action [5].

3. Activation of type I IFN response in acute and chronic HIV-1 infection

HIV-1 infection is usually acquired by sexual mucosal transmission. Studies in simian immunodeficiency virus (SIV) intravaginally infected macaques demonstrate that SIV multiplication is initially confined to the mucosal infection site. Following HIV-1 transmission, there is an eclipse phase of about 10 days during which virus is initially increased at the mucosal site and in local lymphoid tissues, and then systemic spreading begins [22]. In this context, primate models have demonstrated that cytokine responses, including IFN production, are earlier and stronger in mucosal tissues of the genital tract and lower in systemic lymphoid tissues after vaginal SIV inoculation [23]. In particular, IFNs and other antiviral chemokines seem to be produced locally by pDCs recruited to the mucosal sites within 24 h of SIV exposure [24]. Later SIV spread to lymphoid tissues is associated with strong IFNs and IFNβ production at these sites [25]. In lymph nodes, pDCs are the major but not exclusive producers of IFNα that mediated a transient IFNα response during the acute phase of SIV infection [25]. Indeed, the administration of TLR7 and TLR9 antagonist did not impact the SIV load or the acute IFNα response in plasma and had minimal effects on ISG expression in both blood and lymph node, indicating that other cells may be involved in this process (e.g. monocytes/macrophages and myeloid DC) [25,26]. Similarly, IFNα and IFNα mediators (e.g. IP-10) are induced within a few weeks prior to peak viremia during acute HIV-1 infection [27]. Likewise, after SIV infection of rhesus macaques in both peripheral blood and the jejunum, the expression of several IFN-induced restriction factors substantially increased in all CD4+ T cell memory subsets at the peak of acute infection [28]. Alongside the induction of type I IFNs and IFN-related pathways, a robust increase in PRRs was recorded during acute SIV infection in both peripheral blood and gut mucosa, coinciding with viral replication [29]. The pronounced

Table 1

Main characteristics of human IFN system (un update).

| IFN | Members | Main Cellular Source | Receptor | Receptor Expression |
|-----|---------|---------------------|----------|---------------------|
| Type I IFN | IFNα1/13, IFNα2, IFNα4, IFNα5, IFNα6, IFNα7, IFNα8, IFNα10, IFNα14, IFNα16, IFNα17, IFNα21 | pDCs, fibroblasts, macrophages | IFNα receptor R1 and R2 | Ubiquitous expression |
| Type II IFN | IFNγ | Natural killer cells, natural killer T cells, Th1 CD4, CD8 cytotoxic T lymphocytes | IFNγ receptor R1 and R2 | Ubiquitous expression |
| Type III IFN | IFNγ1, IFNγ2, IFNγ3, IFNγ4 | Epithelial cells, hepatocytes, pDCs, myeloid DCs and macrophages | IFNγ receptor R1 | Expressed preferentially by epithelial cells |

C. Scagnolari, G. Antonelli

Cytokine and Growth Factor Reviews 40 (2018) 19–31
ences in the expression pro-
tection, but also to the immunopathology of the infection [9]. However, 
concentration compared to the acute phase and IFN-alpha 
chronic phase of HIV-1 infection. Indeed, during HIV-1 disease pro-
the negative e-
fector expression in T cells might be established early in the infection [31]. The latter suggests that a stereotypical HIV-1-induced IFN pattern 
In vitro 
Table 2

| Type I IFN | Cells | Main Results | Ref. |
|-----------|-------|--------------|-----|
| IFNa, IFNa1, IFNa2, IFNg, IFN-leukocyte | Peripheral blood mononuclear cells, HIV-infected H9 lymphocytes | IFN has a dose-related suppressive effect on HTLV-III replication | 54 |
| IFNa, IFNg | Peripheral blood mononuclear cells, H9 lymphocyte and monocytoid U937 cell lines | IFNs show similar concentration-dependent anti-HIV activity. No reduction in HIV expression are observed when persistently infected H9 cells are treated with high dose of IFN | 56 |
| IFNa2 | Stable cell lines, derived from Vero cells and A3.01 cells, that express IFN gene | The transcription and replication of HIV was completely inhibited by IFN | 57 |
| IFNa | HIV infected H9 lymphocytes | HIV-1 replication is inhibited by a maximum of 22% at 1000 Units/ml of IFN | 58 |
| IFNg | Peripheral blood mononuclear cells | IFN reduces replication of HIV. The effect is most pronounced when high levels of the IFN are employed | 59 |
| IFNa | Promonocytic (U1) and T lymphocyte (ACH-2) cell lines chronically infected with HIV | IFN inhibits the release of RT, viral antigens, the production or release (or both) of whole HIV virions, but has no effect on the amount of cell-associated viral proteins | 60 |
| IFNa, IFNg | Chronically HIV infected monocytoid U937 cells | The addition of 1000 Units of IFN per ml to HIV-infected U937 cells resulted in some inhibition of virus production | 61 |
| IFNa, IFNg | Monocyte-derived macrophage | IFN acts to restrict the formation of proviral DNA | 62 |
| IFNa, IFNg | T cells or monocytes | Levels of RT activity in IFN-treated HIV-infected T cells are half those in control cultures, but the frequency of infected cells or the levels of p24 released in culture fluids are unchanged | 63 |
| IFNa | Chronically HIV infected Lymphocytic ACH-2 and promonocytic U1 cell lines | Monocytes treated with IFNs at the time of virus challenge showed no evidence of HIV infection: no p24 antigen or RT activity, no viral mRNA, and no proviral DNA. Monocytes treated with IFN 7 days after HIV infection are not free of the retroviral pathogen | 64 |
| IFNa, IFNg | HeLa T4 cells | IFNs inhibit syncytium formation induced by HIV-1 envelope glycoprotein and are found to be potent inhibitors of HIV-1 induced cell fusion | 65 |
| IFNa | T-cell, H9, CEM, C3, and Jurkat cell lines | IFN decreases virus production (extracellular RT and p24 antigen levels in the supernatant medium). Chronically infected Jurkat cells treated with IFN appear to be inhibited in growth rate, as virus production decreased with cell number | 66 |
| IFNa | CEM-174 | Pretreatment of cells with 50 to 500 Units of IFN per ml result in a marked reduction in HIV RNA and protein synthesis. IFN-induced inhibition of viral protein synthesis is detected only when cells were treated with IFNa prior to infection or when IFNα are added up to 10 h postinfection, but not if IFNα are added at the later stages of HIV-1 replication cycle or after the HIV-1 infection is already established | 67 |
| IFNa | Peripheral blood mononuclear cell | A marked depletion of envelope glycoprotein (gp120) in HIV virions released from IFN-treated cells | 68 |
| IFNa, IFNg | Monocytes derived macrophage | Macrophages pretreated with IFNs have a reduced HIV DNA signal while the spliced mRNA signal is essentially abolished. No virus is produced. The addition of IFNs does not affect the levels of HIV spliced transcripts in cells with established productive infection | 69 |
| IFNa, IFNg | Chronically HIV infected monocytoid U937 cells and CEM cells | IFN treatment induces a specific block on HIV mRNA translation | 70 |
| IFNa, IFNg | MT4 cells | IFNs block an early step in SIV replication while HIV gene expression was disrupted at a later point. Both the stability and proteolytic processing of HIV specific proteins were altered in IFN-treated cells | 71 |
| IFNa | Monocytes derived macrophage | IFN affect early steps of HIV-1 Bal. replication, preceding the completion of viral DNA synthesis | 72 |
| IFNa | Chronically HIV infected monocytoid U937 cells | IFN affects late stages of HIV-1 replication, by inhibiting virus assembly and release, and by reducing the infectivity of shed virions | 73 |
| IFNa1b, IFNa2a, IFNa2b, IFNg1a | T-cell lines (MT4R5, Jurkat, HUT-78, CEM) and primary CD4 T lymphocytes | IFNs have a limited effect on HIV spread, measured as the appearance of Gag-expressing cells | 74 |
| IFNc | FRT epithelial cancer cell line and Sup-T1 lymphoma line | Cell-to-cell HIV transfer is less sensitive to IFN than infection by cell-free virions | 75 |

IFNa/β response induced during acute HIV-1 infection may also have detrimental effects, contributing to the initial control of viral replication, but also to the immunopathology of the infection [9]. However, the negative effects of type I IFN become more evident during the chronic phase of HIV-1 infection. Indeed, during HIV-1 disease pro-
progression, IFNs occurred in serum with increasing regularity and concentration compared to the acute phase and IFNa was correlated with the occurrence of HIV-1 p24 antigen in serum [30]. Moreover, differences in the expression profile of type I IFN pathways of T cells (CD4 and CD8) were recorded from early HIV-1 infection (infected for less than 6 months) and chronic progressors (infected for more than 1 year) [31]. The latter suggests that a stereotypical HIV-1-induced IFN pattern of gene expression in T cells might be established early in the infection and persist for years thereafter. Like HIV-1 infection in humans, pathogenic SIV infection of non-natural host species, such as rhesus macaques, is associated with a robust type I IFN response and ISG ex-
pression that persist in SIV-infected macaques even though IFNα-producing pDCs are partially depleted from the blood and/or lymph nodes [32–38]. By contrast, non-pathogenic SIV infections (African green monkey and sooty mangabey) display strong pDC activation and type I IFN production during acute SIV infection but low IFNα activation during chronic infection [33,35,38]. Intriguingly, pDCs levels capable of sensing SIV and releasing type I IFNs in nonpathogenic SIV infection seems to be decreased during acute infection [39]. Furthermore, SIV-infected sooty mangabeys are not intrinsically resistant to type I IFN signaling so it should be concluded that the mechanisms involved in the capability of these animals to retain low immune activation/in-
flammation are expected to be multifactorial and not exclusively de-
pendent on IFN/ISG stimulation [40]. In agreement with the results obtained from the primate models of SIV infection, several studies have
reported a strong activation of different components associated with the type I IFN response (e.g. IRFs, ISGs, viral DNA sensors, MYD88, IFNAR) during chronic HIV-1 infection [41–45]. High levels of ISGs such as IFN-α10 were also associated with a more rapid CD4+ T cell depletion [46,47]. Consistent with the above findings, no significant ISG upregulation has been observed in viremic non-progressors, and global T-cell gene expression profiles of IFN-related genes in nonprogressors appeared similar from those with no HIV-1 infection [31,44,48,49]. The notion that IFN pathways are increased during persistent HIV-1 replication is also supported by the observation that a large ISGs group were down-regulated in lymph node biopsy samples in post-HAART therapy [50]. Moreover, the interruption of HAART is accompanied by increased mucosal gene expression of IFN-mediated antiviral responses, a profile similar to those found in naïve HIV-1 infected patients [51]. Although prolonged antiretroviral treatment can improve GALT immune function, the type I IFN response in gut seems to persist in long-term treated HIV-1-infected patients [52]. This finding could be due to the rapid pDC migration to the intestinal and lymphoid tissues after acute SIV infection, causing a local inflammation with type I IFN production [53].

4. IFN mechanism of action during HIV-1 infection

A complex and seemingly paradoxical role of type I IFNs in HIV-1 infection has been well documented [1,2]. The pronounced type I IFN response induced during HIV-1 infection may likewise have detrimental effects. Although IFN is produced during HIV-1 infection, it is not able to inhibit early infection and a persistent IFN-mediated immune activation becomes one of the main pathogenic mechanisms of HIV-1 disease. On the contrary, IFNα administration initially upregulated expression of ISGs and prevented systemic infection in a pathogenic SIV rhesus macaque model using intrarectal challenge [15], suggesting a positive action of IFN in controlling early viral infection. However, IFNα treatment also resulted in accelerated CD4+ T cell depletion and increased viremia, probably due to the activation of IFN-related desensitization mechanisms induced by continued treatment [15]. Hence, type I IFN response during HIV-1 infection, as discussed below, could exert positive and negative effects indicating its dual role in regulating and promoting both HIV-1 infection and immunopathogenesis.

4.1. Anti-HIV activity

Several groups have demonstrated that type I IFNs inhibit HIV-1 replication in human cells cultivated in vitro [54–73]. These studies identified multiple mechanisms by which type I IFNs can affect the HIV-1 infectious cycle, determined by the target cells and the timing of IFN addition and virus infection (Table 2). In particular, IFNot/β treatment of primary T lymphocytes, monocytes/macrophages, and some T cell lines before HIV-1 infection efficiently suppresses the early steps of the virus life cycle, including HIV-1-induced cell fusion, viral RNA, DNA and protein production (Table 2). However, it appears that the mechanisms by which type I IFNs inhibit HIV-1 replication in T cells and macrophages were not identical. While the principal effect of IFN in infected T cells or primary lymphoblast cultures was on the terminal stage of the HIV-1 life cycle (e.g. assembly and release) and HIV-1 morphogenesis [66,68], IFN in macrophages appears to interrupt an early step of the HIV-1 replication cycle (Table 2). Moreover, monocytes treated with type I IFN a week after HIV-1 infection were not free of the retroviral pathogen: levels of proviral DNA in the IFN-treated and control HIV-infected cells were indistinguishable [63]. Similarly, IFN-induced inhibition of viral protein synthesis could be detected in T cells only when cells were treated with IFNα prior to infection or when IFNα was added up to 10 h postinfection, but not if IFNα was added at the later stages of HIV-1 replication cycle or after HIV-1 infection was already established [67]. IFNα/β also impair later stages of the HIV-1 replication cycle, especially in persistently infected cells cultures, ranging from deregulation of viral protein processing and protein stability, impaired gp120 incorporation and morphogenesis, to altered virion release [60,70–73]. However, the effects on chronic HIV-1 infection seem to be much less pronounced, and very high concentration of IFNs (in some cases exceeding 1000 International Units/ml) were used in the experiments since the effects were absent or negligible at the doses shown to be effective against the majority of lytic viruses. Moreover, the long-term efficacy of IFNs on HIV-1 spread in T cells, measured by following Gag-expressing cells, seems to be less potently inhibited by IFNs [74]. In particular, a gradual increase in the percentage of HIV-1-infected cells over time was observed in T cells exposed to high HIV-1 doses [74]. Virus emergence was the result of suboptimal suppression of HIV-1 multiplication and cell-to-cell transfer was only moderately sensitive to type I IFNs [74]. Thus, the molecular nature of HIV-1 inhibition by IFNs appears to be cell type dependent and multiple parameters like the infectious dose, the time of IFN addition and the subtypes of IFNs used in the experiments should be carefully considered when interpreting the results. This situation is exemplified by the observation that other subtypes within type I IFN other than IFNα/β, such as IFNγ, can strongly suppress HIV-1 replication at multiple stages of infection [75]. In addition, closely related lentiviruses appeared to be inhibited by type I IFNs at different stages of expression in T cells (Table 2), highlighting the complexity of the phenomenon [71]. All together these limitations emphasize the risk of extrapolating results obtained under in vitro conditions to clinical applications in HIV-1-infected patients, explaining in part why the in vitro anti-HIV potency of IFNs generally contrasts with their poor clinical efficacy.

4.2. Detrimental effects

Several mechanisms have been proposed to explain the negative action of type I IFNs in HIV-1-infected patients (Fig. 1). First of all, type I IFNs could partly trigger chronic immune activation by inducing ISGs and chemokines able to attract target cells to the initial site of HIV-1 replication [24]. In this regard, the SIV macaca model showed the induction of an endocervical mucosal signaling system involving MIP-3α, also known as CCL20, and the production of IFNα and virus-inhibiting chemokines by pDCs and T cells, which create an environment rich in target cells, CD4+ T cells and CCR5+ T cell at the sites of initial infection [24].
Second, a role for IFNα in TRAIL/DR5-mediated apoptosis and immunopathogenesis has been proposed [76]. In particular, HIV-1-stimulated TRAIL production was IFNα dependent and mediated by STAT-1/2, antibodies against IFNα/β block TRAIL production and apoptosis of HIV-1 exposed CD4T cells, while IFNα produced by HIV-1-exposed pDCs was responsible for TRAIL expression on primary CD4T cells [41, 76–78]. Importantly, increased mRNA expression for IFNα, TRAIL and DR5 was recorded in tonsils of patients with progressive HIV-1 disease compared to tonsils of patients with nonprogressive disease [41]. Uregulated TRAIL expression was also observed in HIV-1-positive patients with high levels of ISGs (e.g. ISG15) and viremia [45]. Besides the relationship between IFNα and TRAIL/DR5-mediated apoptosis, in chronic HIV-1 infection the pro-apoptotic Bak was found increased in CD4T cells and correlated positively with sensitivity to Fas/CD95-mediated apoptosis and negatively with CD4T cell numbers [79]. Moreover, a model in which CD4T cell-intrinsic type I IFN signaling due to microbial exposure was recently proposed to potentiate gut CD4T cells for accelerated HIV-1 by inhibiting CDK4/6, cyclins and c-Myc [80].

Third, as reported in other viral infections, highly potent immunosuppressive programs mediated by IL-10 and PD-L1 that reduce T cell responses might be responsible for the harmful effects of IFNα/β also in chronic HIV-1 infection [1, 81].

Lastly, a relationship between type I IFNs, thymopoiesis and the HIV-induced immunodeficient state has been observed. Thymus dysfunction is known to characterize HIV-1/SIV infections and contributes to their pathophysiology. In human thymus, thymocytes and medullary pDCs constitutively express IFNα and type I IFNs can suppress thymic output, further limiting CD4T cell recovery [82]. A strong alteration of both chemokines and IFNα subtype transcriptional patterns in SIV-infected thymuses was also recorded, and the IFNα subtypes produced in the infected thymuses inhibited thymocyte proliferiation [82]. Moreover, HIV-1 infection of the human thymus results in increased levels of IFNα. These are associated with MHC I upregulation on thymic epithelial cells and subsequent preferential selection of CD4+CD8+ (SP8) thymocytes with a low level of CD8 expression which may contribute to the generalized immunosuppression [83]. CCR5 expression was also induced by IFNα in thymic organ cultures, suggesting that IFNα may paradoxically expand the tropism of R5 HIV-1 and, in so doing, enhancing viral infectivity in the HIV-1 infected patients [84].

5. Factors affecting the type I IFN response during HIV infection

It is well-documented that type I IFNs and/or ISGs might exert deleterious effects during HIV-1 infection [1, 2], although the actual relationship between IFN response and HIV-1 infection is still a matter of debate. Indeed, the differential effects of age, gender, host genetics, immune environments and cell type on the overall outcome of type I IFN signaling in HIV-1 infection remain unexplained. Also unknown is the main type I IFN subtypes expressed during acute and chronic HIV infection. Translational studies are needed to establish the magnitude of the effects of microbiome composition on IFN activation in HIV-1-infected individuals. Lastly, it has become important to understand the impact of mechanisms of refractoriness to type I IFN activated during HIV-1 infection. Below, the main factors affecting the type I IFN response during HIV-1 infection are discussed, providing some evidence detailing the role of IFNα in this picture.

5.1. Mechanisms of HIV resistance to type I IFN

HIV-1 antagonism against type I IFN production and their anti-viral responses strongly support the concept that IFNs have the innate potential to control HIV-1 infection. In vitro type I IFNs can inhibit HIV-1 infection, and many of the ISGs (e.g. retroviral restriction factors) have strong anti-HIV potency [85]. However, HIV-1 is able to replicate in vivo even in the presence of type I IFNs and ISGs, though the mechanisms by which HIV-1 is able to persist remain mysterious. It is known that the inadequacy of HIV-1 transmission across mucosal surfaces is illustrated by a stringent population bottleneck, in which only one or a limited number of variants with improved transmission fitness from the diverse quasispecies of the transmitting donor are able to start the new infection. In this regard, HIV-1 TF viruses seem to be phenotypically distinct. Increased type I IFN resistance is the key feature to elucidate their ability to replicate and spread efficiently despite a potent mucosal innate immune response [86, 87]. Moreover, HIV-1 TF viruses are uniformly resistant to IFITMs, a requirement that is lost during chronic infection, in part due to escape mutations acquired in response to autologous neutralizing responses [88]. Besides the demonstration that TF viruses can overcome the antiviral action of IFNα/β and specific ISGs, several in vitro studies have shown that HIV-1 inhibits type I IFN induction, mainly through its interaction with IRF
members in its three most important target cells: CD4T cells, macrophages, and DCs [89–91]. Remarkable multiple evasion strategies can be employed by HIV-1 to block type I IFN induction and action (Fig. 2). In particular, HIV-1 has evolved to use host cofactors, such as CPSF6 and cyclophilins recruited to its capsid, to cloak its miltiplaction, permitting evasion of PRRs and cGAS, and type I IFN secretion and inhibition of an antiviral state [92]. Further defects in innate viral sensing during HIV-1 infection involve the PRRs, cGAS and IFI16 by inducing TREX1 expression and inhibiting NF-κB activation by HIV-1 Vpu [93]. Moreover, an impaired TLRs and RIG1 response can be recorded during HIV-1 infection [93]. HIV-1 can also affect PRR-mediated signaling through the inhibition of several downstream effectors including IRF3 and IRF7 levels and/or activity [89,90,93]. Following type I IFN production, HIV-1 can also subvert their mechanism of action (Fig. 2). Specifically, HIV-1 can stimulate the production of SOCS3, a molecular inhibitor of IFN signaling, impairing phosphorylation of STAT1/2 [94]. Moreover, downregulated IFNAR expression and consequent hyporesponsiveness to IFNα in PBMC of HIV-1-infected patients has been recorded, although the specific evasion mechanism employed by HIV-1 is currently undefined [95,96].

Lastly, several ISGs can be blocked by HIV-1, including well-established antiviral proteins (e.g. PKR, 2-5 OAS, and ISG15) and the recently identified retroviral restriction factors (e.g. APOBEC3, BST-2, and Mx2) [85,93]. Controversial results have been reported on the ability of type I IFNs to directly induce the restriction factor, namely SAMHD1 [97,98]. However, besides the established ability of HIV-2 to subvert SAMHD1 activity through the vpx gene, SAMHD1 can be regulated by type I IFN treatment by phosphorylation at threonine 592 and IRF3 can be responsible for the direct induction of SAMHD1 [93,99]. Hence, it is clear that in order to replicate efficiently, HIV-1 has evolved multiple strategies to circumvent the ‘first line of defense’ embodied by type I IFN. It is probable that most (if not all) antiviral effectors activated by HIV-1 infections are to some degree circumvented by a virus strategy. Nevertheless, the modes of action of most ISGs remain unclear as do the strategies required by HIV-1 to allow it to circumvent particular IFN responses. Determining the mechanisms by which these ISGs function at different steps of the HIV-1 replication cycle and how the virus-cell interplay subsequently reshapes the host defense mechanisms would be interesting to gain a complete understanding of the molecular basis of the HIV-1 host interaction in the immunopathogenesis of HIV-1 disease.

5.2. Host factors

Different host factors, such as age, gender, specific molecular pattern and cell environments could affect the magnitude of type I IFN activation during HIV-1 infection. However, their relative influence in HIV-1 infection remains poorly understood. Despite these limitations, marked sex differences in type I IFN expression have been described in the course of HIV-1 disease (100, 101). In particular, pDCs from women have been shown to exhibit a stronger IFNα response to HIV-1-encoded TLR7 ligands than pDCs from men, causing a higher secondary activation of CD8 T cells [100]. Expression levels of a subset of ISGs, including ISG15, MxA, and CCR5, were also found to be higher in naive HIV-1 infected females than in males after adjusting for HIV-1 RNA levels and to be associated with elevated levels of immune activation in HIV-1 infection [101].

Few studies have attempted to characterize the influence of patient age on the production of type I IFNs, demonstrating an age-related dysregulation of the capacity to synthesize IFN and ISGs during HIV-1/SIV infection [102].

As far as the genomic study of type I IFNs is concerned, a major problem is the high number of genes (e.g. IFNa, IFNb, IFNc, IFNd, IFNε, IFNσ) or ‘pseudo’-genes (13 different IFNα subtypes), numerous type I IFN signaling pathway components and ISGs [16]. However, several studies have pointed out the importance of SNP related to the type I IFN pathways on the clinical outcome of HIV-1 disease [103–117]. Rapid progression of HIV-1 infection, altered viral load and CD4T cell count were associated with TLR9 polymorphisms [103–105]. Further, genetic variations of TLR4 were more common among HIV-1-positive individuals with high peak viral load compared with low/moderate peak viral load [106]. SNPs in other PRR genes (i.e. IFI16) involved in the HIV-1 genome sensor have also been identified [107]. Exhaustive genotyping of the IFNAR1 gene in a French AIDS cohort disclosed an IFNAR1 protein variant associated with AIDS progression or susceptibility to HIV-1 infection [108]. Additionally, SNPs associated with progression from HIV-1 infection to AIDS were identified in two 2'-5' OAS genes (e.g. OAS2 and OAS3) [109]. In contrast, other SNPs identified in OAS2 and OAS3 genes and in the TRIM5 gene were associated with a slower progression of disease [109]. Several studies have reported controversial results on the influence of retroviral restriction factor SNPs (e.g. APOBEC3, SAMHD1, and BST2) on HIV-1 disease status [110–117]. Although the clinical relevance of these genetic variants during HIV-1 infection has been emphasized, their biological significance has seldom been examined [45,118]. In this regard, two SNPs of IRF-7, both located at intron/extron boundaries, were significantly associated with decreased levels of IFNα production by pDCs in response to HIV-1 [118]. Furthermore, no effects of SNPs located within the 5’UTR region and in the exon 2 structure of ISG15 expression in HIV-1-infected patients were recorded [45]. Besides the analysis of these genetic variants related to the IFN response in HIV-1-positive patients, few studies have looked at the type III IFNs SNPs so far. IFNα/3/IL28B has attracted much attention from HCV researchers because in 2009 genome-wide association studies identified an association between certain SNPs located in the upstream region of IFNα3 and both spontaneous and IFN treatment-induced viral clearance in chronic HCV infection [5,19]. Interestingly, the original SNP (rs12979860) identified near IFNα3 has now been positioned within an intron of the gene encoding the newly discovered IFNλ4 [20]. Importantly, these IFNα3/4 SNPs have been reported to affect IFNα and ISG production, particularly in the liver of HCV-infected patients before or after IFNα or DAAs therapy [5].

Discordant results have been obtained on the clinical significance of IFNλ3/4 SNPs in HIV-1 infection [119–125]. On the one hand, IFNα3/4 SNPs have been associated with unfavorable clinical and immunological status, increased susceptibility to cytomegalovirus reinitis, and protection against HIV-1 disease progression in controllers. On the other, the same SNPs had no effects on clinical outcome or susceptibility to HIV-1 infection.

As far as the biological significance of type III IFN SNPs in HIV-1 infection is concerned and considering that both types I and III IFN share the same JAK-STAT pathway, endogenous ISGs expression in PBMCs from HIV-1-positive patients seems to be independent of the IFNα/4 rs368234815 ΔG/T T dinucleotide polymorphism [126].

5.3. Type I IFN subtypes

12 Despite many indications on a type I IFN signature in HIV-1 infection [1,2], the predominant type I IFN species, and perhaps IFNα subtype, that is upregulated in HIV-1-infected patients has not been conclusively determined. One of oldest studies on the history of IFN and HIV-1 reported an acid-labile human leukocyte IFN in homosexual men with Kaposi’s sarcoma and lymphadenopathy [127]. High levels of IFNα or IFNβ were also detected in sera from HIV-1-infected patients, but other type I IFN subtypes were not analyzed to provide a quantitative comparison [30,128,129]. One of the first studies on this topic was done by Gendelman et al., examining IFNα, IFNβ, and IFNα expression in HIV-1-infected monocytes [130]. However many years later, IFNα was shown to be the main type I IFN measurable in the peripheral blood of HIV-1-positive subjects [131]. Although the latter work reported elevated IFNα expression in HIV-1 infection, the extent of IFNα subtype upregulation has not been investigated. Some attempts have
been made to tackle this issue in recent years. In particular, a
preferential upregulation of IFNα subtype 2 expression has been recorded
in HIV-1 positive patients [132]. Using a pigtailed macaque SIV model,
Zaritsky et al. also demonstrated that IFNα subtype expression and
regulation differ between brain, lung, and spleen [133]. Furthermore,
in response to oral pathogenic SIV infection, multiple IFNα subtypes
(IFNα1/13, IFNα2, IFNα4, IFNα6 and IFNα8) are quickly induced in
lymphoid but not at mucosal surfaces of the oral and gastrointestinal
tracts [134]. A more recent next-generation sequencing study also
analyzed the expression of all IFNα subtypes in HIV-1-exposed pDCs
[135]. It was found that IFNα subtype mRNAs from the centromeric
half of the IFNA gene cluster were highly expressed in pDCs following
HIV-1 exposure. An inverse relationship between IFNα subtype ex-
pression and potency was recorded: IFNα8, IFNα6 and IFNα14 were the
most potent in blocking HIV-1 infection, while IFNα2 and IFNα1 were
both highly expressed but exhibited relatively weak antiviral activity
[135]. In agreement, the IFNα14 subtype has been shown to possess
potent anti-HIV-1 activity compared to other IFNα subtypes and gene
therapy with plasmids encoding IFNβ and IFNα14, but not the com-
monly used IFNα2, conferred long-term suppression of HIV-1 replica-
tion in humanized mouse models [136,137]. Thus the following new
concepts have emerged from these studies: i) HIV-1 induces different
expression patterns of type I IFN subtypes; ii) the production of in-
dividual IFNα subtypes can differ in relation to the cell type and an-
tomical site analyzed; ii) different IFNα subtypes can mediate distinct
anti-HIV-1 effects, indirectly suggesting that different type I IFN pre-
parations might provide different therapeutic outcomes of HIV-1 in-
fection.

5.4. The interplay between the microbiome and the IFN response

It is known that, during the early HIV-1 infection, the initial and
main pronounced depletion of CD4T cells generally occurs in the gas-
trointestinal mucosa [138], where the elevated levels of CCR5-express-
ing CD4T cells within the gut may permit HIV-1 entry and replication
[139]. Chronic HIV-1 infection within the gastrointestinal tract, and the
closely related secondary decrease in CD4T cells significantly shape gut
physiology, thus leading to a dysregulation of the mucosal immune-
epithelial network [140]. In addition to its direct role in changing the
gastrointestinal CD4T cell compartment, it is widely established that
HIV-1 infection is characterized by gut microbiome compositional and
functional changes. Gori et al. were the first to study gut microbiota in
the early phases of HIV-1 infection and found an high abundance of
Pseudomonas aeruginosa and Candida albicans as well as lower levels in
other microbial species, e.g., Bifidobacteria and Lactobacilli, in the
fecal microbiota compared to those reported for healthy individuals
[141]. Nevertheless, the exact microbiome configuration in naive HIV-1
positive individuals, HAART-treated patients and healthy subjects re-
mains still inconsistent [142,143]. Below we first attempt to briefly
describe the gut microbiome composition in HIV-1 infected patients and
then we discuss on the emerging novel concepts concerning the inter-
action between gut microbiota and IFN immune response.

5.4.1. Gut microbiota alterations associated with HIV-1 infection

Previous studies indicated that HIV-1 infection has an impact on the
intestinal microbiota composition, given that HIV-1 infection was as-
associated with enhanced bacterial populations in the gut that are pro-
inflammatory, and so potentially pathogenic, and whose abundance
parallel the inflammatory status and immune recovery [144,145]. In

Fig. 3. Major findings about gut microbiota compositions in HIV-1 infected patients (adapted from [144,145]).

C. Scagnolari, G. Antonelli

Cytokine and Growth Factor Reviews 40 (2018) 19–31
particular, despite considerable experimental variability (e.g. types of samples evaluated; treated or not treated subjects, techniques used to characterize microbiota) the main findings of these investigations were the following: first of all, HIV-1 infection was associated with reduced bacterial richness [144,145]. In particular, diminutions in α diversity have been observed in HIV-1-infected subjects compared to uninfected subjects in both mucosal and fecal samples [144,145]. A greater fecal microbial diversity has been recorded in MSM than in those non-MSM; importantly such a reduction in bacterial richness persists even when HIV-1-positive patients were stratified for MSM vs. non-MSM [146]. This decrease in diversity positively correlated with CD4T cell counts and inversely correlated with markers of microbial translocation and monocyte activation. Surprisingly, HAART did not result in significant changes of the gut microbiota towards increased, and hence beneficial, gut microbiome diversity [144,147].

Alterations in bacterial community composition were typically observed in the 3 most dominant phyla detected in the proximal gut: Proteobacteria, Bacteroidetes and Firmicutes (Fig. 3).

In this context, an overall enrichment of members of the phylum Proteobacteria and decreased abundances of Firmicutes were observed in the HIV-infected tissue and stool samples of both untreated and treated HIV-1 infected individuals [144,145]. Unexpectedly, a significant decrease in the abundance of Firmicutes was observed in HIV-infected patients using NRTIs + PIs compared to uninfected controls, suggesting that specific HAART regimens are associated with diverse profiles in gut microbiota composition [151].

At the family level, the relative abundance of Prevotellaceae seems to be higher in HIV-1 infected subjects whereas Lachnospiraceae, Christensenellaceae, Ruminococcaceae and Bacteroidaceae were all lower in HIV-1 infected subjects relative to uninfected individuals [148].

Furthermore, when bacteria were evaluated to the genus level, enrichment for Burkholderia, Acinetobacter, Schigella, Klebsiella, Salmonella, Rahnella were observed in HIV-1 infected patients (Fig. 3) [146,149]. In contrast, Lactobacillus, within Firmicutes phylum, were reduced in duodenal tissue from naive HIV-1 positive individuals, and higher Lactobacillus abundance was also found in fecal samples of a cohort of untreated subjects with early HIV-1 infection with higher CD4 counts, lower viral loads and reduced microbial translocation and, interestingly, these associations continued following HAART [144,145,150].

Although it is difficult to draw definite conclusions, it appears that HIV-1 positive patients microbiota is characterized by an increase in potentially pathogenic bacteria and, conversely, a decrease in protective bacteria populations. However, it should be underlined that a complete definition of HIV-1 as well as healthy microbiota is still incomplete given that a myriad of factors can influence the composition of gut microbiome [152]. Since the gut microbiota exhibited immune-modulating qualities and considering that the components of the microbiota can directly contribute to CD4T cell depletion in HIV-1 infection and can regulate the gut T helper subset-related immune homeostasis [152], it is tempting to speculate that a better characterization of the complex interactions between microbial dysbioses and the mucosal immune system is critical to improve our understanding of the functional aspects of microbiome as a key or additional driver of HIV-1 disease.

5.4.2. Interaction between IFN response and microbiome

It is known that the cross-talk between the gut microbiome and host is extensive, and involves both innate and adaptive immunity. It is established that HIV-1 infection upsets the delicate equilibrium in the host-microbe interplay through both alterations in the gut microbiome (see above) and interference with the host response mechanisms [152].

In this regard, it has been reported that endogenous type I IFN response induced by signals from the commensal microbiota can affect the local signaling environment to prime the intestinal mucosal immune system to determine later responses to pathogens and commensal organisms [153]. However, it has yet to be determined if the microbiota dysbiosis of HIV-1-infected patients could influence the local and/or systemic innate antiviral immune response including not only type I IFN production but also that associated with IFNA, expression, which is known to use a specific receptor preferentially expressed at the mucosal surfaces. In this context, a remarkable dampening of PRR expression was recently observed in gut mucosal tissues from acute to chronic SIV infection in rhesus macaques [29]. Decreased PRR expression was associated with increased abundance of numerous pathogenic bacterial taxa, including Pasteurellaceae members, Aggregatibacter and Actinobacillus, and the Mycoplasmataceae family, which in turn might be responsible for promoting persistent IFN activation, gut microbiota alterations, and limited viral clearance [29]. Despite a reduced expression of PRR, microbial exposure influenced how HIV-1 altered the gut CD4T cell transcriptome causing a strong upregulation of type I IFN and ISG production [80]. Surprisingly, the induction of multiple antiviral genes after microbial exposure was also associated with an enhanced TF HIV-1 replication [80]. In agreement, our previous study recorded a strong activation of IFNa/β and its receptor in the gut mucosa of HIV-1-infected subjects [52]. Moreover, our preliminary observations suggest a link between microbiota composition and type I IFN signature in HIV-1-positive patients (unpublished data). All these studies emphasize that the dysregulated IFNa/β and ISG levels observed during HIV-1 infection could be at least in part determined by the specific microbiota composition. This hypothesis is supported by the following recent findings. First of all, commensal bacteria can calibrate the activation threshold of innate antiviral immunity [154]. In particular, a tonic signaling by type I IFNs on antigen-presenting cells is required for efficient viral recognition and generation of adaptive immunity, and this signal is provided by commensal bacteria in the steady state. Second, type I IFN receptor functions on intestinal epithelial cells to restrain Paneth and goblet cells and to shape the microbial composition [155]. Third, the bacterial microbiome can foster enteric viral persistence (e.g. norovirus) in a manner counteracted by specific components of the innate immune system (e.g. type III IFNs) [156, nice].

Besides the ability of the microbiota to modulate the IFN response through as yet unclear mechanisms, specific components of the enteric microbiota (i.e. microbial metabolite desaminotyrosine) have been shown to exert distal effects on responses to lethal viral infections through modulation of type I IFN [157]. Thus, bacterial products can modulate different components of the innate immune system to potentially facilitate responses to microbial pathogens. Further work is required to define specific mechanisms by which bacteria and/or their metabolites as well as other microorganisms (e.g. virome and mycome) might impact IFN signaling and anti-HIV-1 immunity not only in the intestine but also in other anatomical sites.

6. Conclusions

It is well-established that type I IFNs have direct and/or indirect (through the induction of several mediators) beneficial effects on innate and adaptive immune cells during viral infection. It is now known, however, that while low levels of type I IFNs may be required at an early stage to initiate cell-mediated immune responses, high concentrations may lead to the production of immunosuppressive molecules. Type I IFN-induced virus protection, immunopathology or autoimmunity also seem to be a matter of kinetics other than magnitude. In particular, delayed type I IFN production has been implicated in the promotion of viral disease [12]. It is tempting to speculate that when viral infections cannot be cleared persistent type I IFN activation assumes a principally immunosuppressive role, probably to reduce host toxicity during chronic infection. Then, type I IFN-induced negative regulatory pathways represent one of the major drivers of persistent inflammation/immune activation and disease progression in chronic viral infections such as those caused by HIV-1 or HCV [1,2,5]. However, the role of type I IFNs in chronic virus infections is complex, often
leading to different outcomes depending on the timing, host cellular environment present, the cumulative amounts of type I IFN components, and the specific IFN subtypes mediating the biological effects. This suggests that during viral diseases a balanced network of type I IFNs does exist to provide protection with minimum damage to the host, but is still largely unknown. Indeed, although we have wide knowledge of the variety of signaling pathways activated by the IFN system, the links between specific pathways and distinct outcomes are not well-understood, especially in a complex viral disease such as HIV-1 infection. In this regard, the observations that an elevated type I IFN signature can be deleterious in chronic HIV-1 infection together with the difficulties encountered in the in vivo manipulation of type I IFN signaling [15] should prompt us to reflect on whether we have properly investigated the therapeutic potential of IFNαs in this clinical setting. For instance, since its first use in the early 1980s as a promising therapy for HIV-1, we started IFNα therapy in HIV-1-infected patients regardless of whether the pre-existing elevated type I IFN signature could render the patient intrinsically resistant to IFN therapy. Therefore, as “veterans” of the lesson on ISG-mediated resistance to IFN therapy in HCV infection [5], are we again wrong to evaluate, but above all “render the patient intrinsically resistant to IFN therapy. Therefore, as the di

signature can be deleterious in chronic HIV-1 infection together with infection. In this regard, the observations that an elevated type I IFN system, the links between specific signaling pathways activated by the IFN

test in HIV-1/SIV infection, J. Virol. 20 (2014) 1237–1245.

[7] E.B. Wilson, D.H. Yamada, H. Ehsaesi, J. Herskovitz, J. Deng, G. Cheng, B.J. Aronow, C.L. Karp, D.G. Brooks, Blockade of chronic type I interferon signaling to control persistent LCMV infection, Science 340 (2013) 202–207.

[8] J.R. Teijaro, Too much of a good thing: sustained type I interferon signaling limits humoral responses to secondary viral infection, Eur. J. Immunol. 46 (2016) 300–302.

[9] N. Honke, N. Shabani, K. Merches, A. Gassa, A. Kraft, K. Ehrhardt, D. Häussering, M. Löhnig, U. Dittmer, H. Hengel, M. Recher, P.A. Lang, K.S. Lang, Immunoactivation induced by chronic viral infection inhibits viral replication and drives immunosuppression through sustained IFN-α responses, Eur. J. Immunol. 46 (2016) 372–380.

[10] C.R. Baskin, H. Bielefeldt-Ohmann, T.M. Tumpey, P.J. Sabourin, J.P. Long, A. García, A.E. Sastre, R. Tolnay, J.A. Albrecht, H.P. Fyles, L.D. Olson, E.R. Aicher, K. Ensslenweig, E.A. Murrali-Krishna, M.S. Clark, J.L. Kotur, S. Formek, R.E. Proll, C.L. Palermo, M.S. Gudkov, Early and sustained innate immune responses define pathology and death in nonhuman primates infected by highly pathogenic influenza virus, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 3455–3460.

[11] S. Davidson, S. Crotto, T.M. McCabe, A. Wack, Pathogenic potential of interferon α in acute influenza infection, Nat. Commun. 5 (2014) 3864.

[12] R. Channappanavar, A.R. Fehr, R. Vijay, M. Zack, J. Zhao, D.K. Mershel, S. Perlman, Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice, Cell Host Microbe 19 (2016) 181–193.

[13] L. Cheng, J. Ma, J. Li, D. Li, G. Li, Q. Zhang, H. Yu, F. Yasui, C. Ye, L.C. Tsao, Z. Hu, L. Su, L. Zhang, Blocking type I interferon signaling enhances T cell reactivity and reduces HIV-1 reservoirs, J. Clin. Investig. 127 (2017) 1260–1271.

[14] A. Zhen, V. Rezek, C. Youn, B. Nam, C. Jiang, J. Rick, M. Villriou, H. Martin, S. Kasparian, P. Syed, N. Rice, D.G. Brooks, S.G. Kitchen, Targeting type I interferon-mediated activation restores immune function in chronic HIV infection, J. Clin. Investig. 127 (2017) 2374–2387.

[15] N.G. Sandler, S.E. Bosinger, J.D. Estes, R.T. Zhu, G.K. Tharp, E. Boritz, D. Leivan, S. Wijeyesinghe, K.N. Makamuppul, G.Q. del Prete, B.J. Hill, J.K. Timmer, E. Reiss, G. Yarden, S. Darko, E. Conticchio, J.P.P. Todd, G. Silvestri, M. Nason, R.B. Norgren Jr., B.F. Keele, S. Ryan, K. Langford, D.D. Lifson, D.C. Durek, Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression, Nature 511 (2014) 601–605.

[16] K. Gibbett, J.F. Schlau, D. Yang, U. Dittmer, IFN-α subtypes: distinct biological activities in anti-viral therapy, Br. J. Pharmacol. 168 (2013) 048–58.

[17] R. Asokan, H. Kua, K.A. Young, H.J. Gould, J.P. Hannan, D.M. Kraus, G. Szakonyi, G.J. Grundy, X.S. Chen, M.K. Crow, V.M. Holers, Characterization of human complement receptor type 2 (CR2/C21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus, J. Immunol. 177 (2006) 383–394.

[18] S.V. Kotenkov, G. Gallagher, V.V. Baurin, A. Lewis-Antes, M. Shen, N.K. Shah, J.A. Langer, F. Sheikh, H. Dickensheets, R.P. Donnelly, IFN-λs mediate anti-viral protection through a distinct class II cytokine receptor complex, Nat. Immunol. 4 (2003) 69.

[19] E. Riva, C. Scagnolari, O. Turriziani, G. Antonelli, Hepatitis C virus and interferon type I (interferon-α/interferon-β and interferon-α/γ): genetic basis of susceptibility to interferon and response to antiviral treatment, Clin. Microbiol. Infect. 20 (2014) 1237–1245.

[20] L. Prokunina-Olsson, B. Muchmore, W. Tang, R.M. Pfeiffer, H. Park, H. Dickensheets, D. Hergott, P. Porter-Gill, A. Mumy, I. Kohaar, S. Chen, N. Brand, M. Tarway, L. Liu, F. Sheikh, J. Astemborski, H.L. Bondovsky, B.R. Edlin, C.D. Howell, T.R. Morgan, D.L. Thomas, B. Rehermann, R.P. Donnelly, T.R. O'Brien, A variant upstream of IFNL3 (IL28B) creating a new interferon gene family, Science 340 (2013) 207–211.

[21] G. Uzt, D. Monneron, L-28 and IL-29: newcomers to the interferon family, Biochimie 89 (2007) 729–734.

[22] A.T. Haase, Targeting early infection to prevent HIV-1 mucosal transmission, Nature 464 (2010) 217–223.

[23] K. Abel, D.M. Rocke, B. Chohan, L. Frith, C.J. Miller, Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection, J. Virol. 79 (2005) 1216–12172.

[24] Q. Li, J.D. Estes, P.M. Schieve, L. Dean, A.J. Bromrah, P.J. Souza, C.S. Reilly, M.L. Peterson, N. Schultz-Darken, K.G. Brunner, K.R. Nephew, S. Pambuccian, J.D. Lifson, J.V. Carls, A.T. Haase, Glycerol monolaurate prevents mucosal SIV transmission, Nature 10 (2009) 1034–1038.

[25] M. Kader, A.P. Smith, C. Guiducci, E.R. Wonderlich, D. Normolle, S.C. Watkins, T.R. O'Brien, A variant upstream of IFNL3 (IL28B) creating a new interferon gene family, J. Virol. 91 (2017) e02189-16.

[26] A.R. Stacey, P.J. Norris, L. Qin, E.A. Haygreen, E. Taylor, J. Heitman, M. Lebedeva, A. DeCamp, D. Li, D. Grove, S.G. Self, P. Borrow, Induction of a striking systemic inflammatory response in severe acute respiratory syndrome and severe acute respiratory syndrome-associated coronavirus infection, J. Virol. 83 (2009) 3719–3727.

[27] A.R. Rahmberg, P.A. Rajakumar, J.M. Billingsley, R.P. Johnson, Dynamic modulation of expression of lentiviral restriction factors in primary CD4(+)/CD8(-) T cells following simian immunodeficiency virus infection, J. Virol. 91 (2017) e02189-16.
C. Scagnolari, G. Antonelli

Cytokine and Growth Factor Review 40 (2019) 18–31

[29] T.W. Glavan, C.A. Gauke, C. Santos Rocha, S. Sankaran-Walters, L.A. Hizao, M. Raffaelli, G. Jiang, A.J. Bäumler, R.L. Gouart, S. Sanderk, Gut immune dysfunction through impaired innate pattern recognition receptor expression and gut microbiota dysbiosis in chronic SIV infection, Mucosal Immunol. 9 (2016) 679–688.

[30] M. von Sydow, A. Sonnerborg, O. Strannegard, Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection, AIDS Res. Hum. Retrovir. 7 (1991) 375–380.

[31] M.D. Byrza, G. Mostowy, R. Halpenny, L. Heister, S. Yang, O. Wilkins, M. Ostrowski, S.D. Der, Distinct transcriptional profiles in vivo CD4+ and CD8+ T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD4+ T cells, J. Virol. 81 (2007) 3477–3486.

[32] S.E. Bosinger, K.A. Hosiawa, M.J. Cameron, D. Persad, L. Ran, Gene expression profiling of host response in models of acute HIV infection, J. Immunol. 173 (2004) 6858–6868.

[33] S.E. Bosinger, Q. Li, S.N. Gordon, N.R. Klatt, L. Duan, L. Xu, N. Francella, M. Rotger, J. Dalmau, A. Rauch, P. McLaren, S.E. Bosinger, R. Martinez, K. Abel, M.J. Alegria-Hartman, K. Rothaeusler, M. Marthas, C.J. Miller, The relationship between simian immunodeficiency virus type 1 infection and IFI16 expression correlates with chronic immune dysfunction through impaired innate pattern recognition receptor expression and SIV replication in vitro, AIDS Res. Hum. Retroviruses 3 (1987) 125–133.

[34] M.P. Sankaran-Walters, M. Syvane, J.K. Wong, M.D. George, S. Dandekar, The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy, J. Infect. Dis. 189 (2004) 572–582.

[35] P. Fischl, G. Cencicarli, M. Andreotti, C. Selvaggi, G. D’Ercole, O. Strannegard, Functional genomic analysis of the response of HIV-1-infected lymphatic tissue to anti-retroviral therapy, J. Infect. Dis. 189 (2004) 572–582.

[36] L. Duan, L. Xu, N. Francella, M. Rotger, J. Dalmau, A. Rauch, P. McLaren, S.E. Bosinger, R. Martinez, K. Abel, M.J. Alegria-Hartman, K. Rothaeusler, M. Marthas, C.J. Miller, The relationship between simian immunodeficiency virus type 1 infection and IFI16 expression correlates with chronic immune dysfunction through impaired innate pattern recognition receptor expression and SIV replication in vitro, AIDS Res. Hum. Retroviruses 3 (1987) 125–133.

[37] D.D. Ho, K.L. Hartshorn, T.R. Rota, C.A. Andrews, J.C. Kaplan, R.T. Schooley, M.S. Hirsch, Recombinant human interferon alpha-A suppresses HTLV-III replication in vitro, Lancet 1 (1985) 602–604.

[38] J.K. Yamamoto, F. Barré-Sinoussi, V. Bolon, N.C. Pedersen, M.B. Gardner, Human alpha- and beta-interferon but not gamma- interferon suppress the in vitro replication of LAV HTLV-III and ARV-2, J. Immunol. 139 (1987) 72–73.

[39] G. Poli, J.M. Orenstein, A. Kinter, T.M. Folks, A.S. Fauci, Interferon alpha but not alpha interferon suppress HIV expression in chronically infected cell lines, Science 244 (1989) 575–577.

[40] C. Locardi, C. Petrini, G. Boccoli, U. Testa, C. Diefenbach, S. Butti, F. Belardelli, Increased human immunodeficiency virus (HIV) expression in chronically infected U937 cells upon vitro differentiation by hydroxyvitamin D3: roles of interferon and tumor necrosis factor in regulation of HIV production, J. Immunol. 64 (1990) 5948–5956.

[41] M. Crespi, The effect of interferon on cells persistently infected with HIV-1, AIDS 1 (1987) 28–31.

[42] B. Michaelis, J.A. Levy, HIV replication can be blocked by recombinant human interferon alpha, AIDS 1 (1987) 72–73.

[43] R.S. Kornbluth, P.S. Oh, J.R. Munis, P.H. Cleveland, D.D. Richman, The role of interferons in the control of HIV replication in macrophages, Clin. Immunol. Immunopathol. 54 (1990) 200–219.

[44] H.E. Gendelman, L.M. Baca, J. Turpin, D.C. Kalter, B. Hansen, J.M. Orenstein, C.W. Diefenbach, R.M. Friedman, M.S. Melzer, Regulation of HIV replication in infected monocytes by IFN-alpha. Mechanisms for viral restriction, J. Immunol. 149 (1992) 1613–1621.

[45] B.F. Ferrie, G. Poli, A.S. Fauci, Alpha interferon suppresses virion but not soluble human immunodeficiency virus antigen production in chronically infected T-lymphocytic cells, J. Virol. 65 (1991) 3968–3971.

[46] E.M. Coccia, B. Krust, A.G. Hovanessian, Species differences of IFN-alpha and -beta action on human T cells, J. Interferon Cytokine Res. 15 (1995) 582–587.

[47] E.M. Coccia, B. Krust, A.G. Hovanessian, Species differences of IFN-alpha and -beta action on human T cells, J. Interferon Cytokine Res. 15 (1995) 582–587.

[48] E.M. Coccia, B. Krust, A.G. Hovanessian, Species differences of IFN-alpha and -beta action on human T cells, J. Interferon Cytokine Res. 15 (1995) 582–587.

[49] E.M. Coccia, B. Krust, A.G. Hovanessian, Species differences of IFN-alpha and -beta action on human T cells, J. Interferon Cytokine Res. 15 (1995) 582–587.
C. Scaglioni, G. Antonelli

Cytokine and Growth Factor Reviews 40 (2018) 19–31

[96] C. Gourjon, T. Scaller, R.P. Galao, S.M. Amie, K. Briveli, S.J. Neil, M.H. Malim, Evidence for IFNα-induced, SAMHD1-independent inhibitors of early HIV-1 infection, Retrovirology 10 (2013) 23.

[97] S. Yang, Y. Zhan, Y. Tong, W. Tong, F. Gao, L. Li, Q. Huang, Z. Ma, G. Tong, Interferon regulator factor 3 is a key regulation factor for inducing the expression of SAMHD1 in antiviral innate immunity, Sci. Rep. 6 (2016) 29665.

[98] A. Meier, J.J. Chang, E.S. Chan, B.R. Pollard, H.K. Sidhu, S. Kulkarni, T.F. Wen, J.R. Lindsay, L. Orellana, D. Mvidan, S. Banzer, H. Streek, G. Alter, J.D. Lifson, M. Carrington, R.J. Bosch, G.K. Robbins, M. Alfred, Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1, Nat. Med. 15 (2009) 955–959.

[99] H.Y. Zheng, M.X. Zhang, M. Chen, J. Jiang, H.J. Song, X.D. Lian, X.L. Zhang, L.T. Zhang, W. Fang, G.H. Zhang, Y.T. Zheng, Accelerated disease progression and robust immune response in the settings of HIV-1 disease due to the host immune response to rhesus macaques is associated with enhanced immunosenescence, Sci. Rep. 7 (2017) 37.

[100] P.Y. Bochud, M. Hemberger, P. Taffe, M.Bochud, C.M. Stein, S.D. Rodrigues, T. Calandra, P. Francisci, A. Teletini, F.R. Speck, A. Aderem,1 Swiss HIV cohort study. polymorphisms in toll-like receptor 9 influence the clinical course of HIV-1 infection, AIDS 21 (2007) 441–446.

[101] N. Soriano-Sarabia, A. Vallejo, R. Remizore-Lorca, M.D. Rodriguez, A. Salinas, J.J. Casado, et al., Inflammation and toll-like receptor 9 expression on monocytes, monocytes, or T cells in HIV-1 infection: correlation with viral load and clinical progression, J. Acquir. Immune Defic. Syndr. 62 (2013) 197–204.

[102] M.E. Keir, M.G. Rosenberg, J.K. Sandberg, K.A. Jordan, A. Wiznia, D.F. Nixon, C.A. Stoddart, M.E. Keir, IFN-alpha-induced upregulation of CCR5 leads to expanded HIV tropism in vivo, PLoS Pathog. 6 (2010) e1000676.

[103] N. van Montfoort, D. Olagnier, J. Hiscott, Unmasking immune sensing of retroviruses: interplay between innate sensors and host effectors, Cytokine Growth Factor Rev. 25 (2014) 518–520.

[104] A. Diop, T. Hirtz, H. Do, C. Coulonges, A. Vaislet, P. Fabre-Mersseman, B. Charmeteau-De Muylder, M. Rancez, C.R. Cunningham, A. Champhekar, M.V. Tullius, B.J. Dillon, A. Zhen, J.R. de la Fuente, J. Hernkovicz, H. Eliazezer, L.M. Smell, E.B. Wilson, J.C. de la Torre, S.G. Kitchen, M.A. Horvitz, S.J. Benninger, S.T. Smale, D.G. Brooks, S. Brooks, A. McLaughlin, T. Hirtz, A. Wiznia, D.F. Nixon, C.A. Stoddart, J.M. McCune, Generation of CD3+ CD8 low thymocytes in the HIV type 1-infected thymus, J. Immunol. 169 (2002) 2778–2786.

[105] J. Dutrieux, V. Fabre-Mersseman, B. Charmeteau-De Muylder, M. Rancez, C.R. Cunningham, A. Champhekar, M.V. Tullius, B.J. Dillon, A. Zhen, J.R. de la Fuente, J. Hernkovicz, H. Eliazezer, L.M. Smell, E.B. Wilson, J.C. de la Torre, S.G. Kitchen, M.A. Horvitz, S.J. Benninger, S.T. Smale, D.G. Brooks, S. Brooks, A. McLaughlin, T. Hirtz, A. Wiznia, D.F. Nixon, C.A. Stoddart, J.M. McCune, UPF3C upregulation of CCR5 during viral persistence, PLoS Pathog. 12 (2016) e1005536.

[106] J. Ouadira, Y. Muller, G. Yang, A.C. Eid, N.E. Mangan, C. Pade, S.S. Lim, A.Y. Matthews, J.A. Fraietta, Y. Mueller, G. Yang, A.C. Boesteanu, D.T. Gracias, D.H. Do, J.P. Herbeuval, A.W. Hardy, A. Boasso, S.A. Anderson, M.J. Dolan, M. Dy, J.P. Herbeuval, A.W. Hardy, A. Boasso, S.A. Anderson, M.J. Dolan, M. Dy, G.M. Shearer, Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11974–11979.

[107] N.I. Rallon, C. Restrepo, S. Naggie, M. Lopez, J. Del Romero, D. Goldstein, J.C. Kappes, C. Ochsenbauer, M.D. McCarter, C.C. Wilson, M.L. Santiago, The impact on thymopoiesis, AIDS 28 (2014) 1101–1113.

[108] J. Mbandinga, S.G. Eid, N.E. Mangan, C. Pade, S.S. Lim, A.Y. Matthews, J.A. Fraietta, Y. Mueller, G. Yang, A.C. Boesteanu, D.T. Gracias, D.H. Do, J.P. Herbeuval, A.W. Hardy, A. Boasso, S.A. Anderson, M.J. Dolan, M. Dy, J.P. Herbeuval, A.W. Hardy, A. Boasso, S.A. Anderson, M.J. Dolan, M. Dy, G.M. Shearer, Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11974–11979.

[109] J.F. Fonteneau, A.S. Beignon, K. McKenna, I. Dasilva, A. Amara, J.F. Lioz, D.R. Littman, B. Bhardawaj, Human immuno deficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells, J. Virol. 78 (2004) 5222–5232.

[110] A. Garcia-Minambres, S.G. Eid, N.E. Mangan, C. Pade, S.S. Lim, A.Y. Matthews, J.A. Fraietta, Y. Mueller, G. Yang, A.C. Boesteanu, D.T. Gracias, D.H. Do, J.P. Herbeuval, A.W. Hardy, A. Boasso, S.A. Anderson, M.J. Dolan, M. Dy, G.M. Shearer, Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11974–11979.

[111] J.F. Fonteneau, A.S. Beignon, K. McKenna, I. Dasilva, A. Amara, J.F. Lioz, D.R. Littman, B. Bhardawaj, Human immuno deficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells, J. Virol. 78 (2004) 5222–5232.

[112] A.S. Lau, S.E. Read, B.R. Williams, Downregulation of interferon alpha but not interferon gamma in HIV-1 infected individuals, Clin. Infect. Dis. 127 (2013) 1386–1393.

[113] A. Garcia-Minambres, S.G. Eid, N.E. Mangan, C. Pade, S.S. Lim, A.Y. Matthews, J.A. Fraietta, Y. Mueller, G. Yang, A.C. Boesteanu, D.T. Gracias, D.H. Do, J.P. Herbeuval, A.W. Hardy, A. Boasso, S.A. Anderson, M.J. Dolan, M. Dy, G.M. Shearer, Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11974–11979.

[114] J.F. Fonteneau, A.S. Beignon, K. McKenna, I. Dasilva, A. Amara, J.F. Lioz, D.R. Littman, B. Bhardawaj, Human immuno deficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells, J. Virol. 78 (2004) 5222–5232.
Guido Antonelli is full Professor of Virology at the Sapienza University in Rome. He is also head of the Microbiology unit and the Department of Diagnostic Services at the “Sapienza” University Hospital “Policlinico Umberto I” in Rome. He took a position at Institute of Virology/Sapienza University (1989) and then at the Department of Biomedicine/University of Pisa (1992); he worked also with the Department of Microbiology, University of Texas Medical Branch (Galveston, Texas, USA) and the Clinical Research Center, Division of Immunological Medicine (Harrow, London, UK). His interest was initially focused on the in vivo and in vitro mechanism of production and action of interferons. His group’s research currently focuses on pathogenesis, control, and diagnosis of viral infections, particularly HIV, HCV, respiratory viruses, and HPV. He participates in several national and international research projects and few years ago served as president of SIVIM (Italian Society for Medical Virology). He has authored and co-authored more than 250 peer-reviewed articles and is now serving as co-editor or member of the editorial board of several peer-reviewed Journals.